TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.
Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs
Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.
Medtronic gains a key approval for Evolut TAVR valves
More patients can now undergo redo TAVR with a Medtronic valve than ever before.
Same-day discharge after TAVR linked to positive outcomes
When low-risk patients undergo transfemoral TAVR, they may be able to go home without spending a single night at the hospital.
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes
Each valve was associated with certain benefits, but one-year outcomes were largely similar.

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

Medtronic gains a key approval for Evolut TAVR valves

More patients can now undergo redo TAVR with a Medtronic valve than ever before.

Same-day discharge after TAVR linked to positive outcomes

When low-risk patients undergo transfemoral TAVR, they may be able to go home without spending a single night at the hospital.

Edwards Lifesciences SAPIEN 3 Ultra TAVR valve

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes

Each valve was associated with certain benefits, but one-year outcomes were largely similar.

PCI just as successful when patients have a history of TAVR—but there are some added risks

Strokes and bleeding complications are more likely when PCI patients have already undergone TAVR, according to a new analysis of ACC registry data.

Video interview with Andreas Ruck, MD, explaining a SWEDHEART registry comparison of Acurate Neo2 to Sapien and Evolut TAVR valves.

Cardiologist highlights safety, effectiveness of Boston Scientific TAVR valve

Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.

When valves fail: Surgeons share advice for treating high-risk patients with TAVR explant and SAVR

When a patient’s TAVR valve fails, redo TAVR is not always a feasible option. TAVR explantation and SAVR are typically the answer in these cases, but that approach is associated with certain risks.